Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase

J Med Chem. 2008 Aug 28;51(16):5118-20. doi: 10.1021/jm800496s. Epub 2008 Aug 6.

Abstract

Anaerobic reduction of anticancer prodrugs is a promising route to achieve targeting and selectivity in anticancer drug design. Most reductive prodrug activations involve simple electron transfer from a flavoprotein and are not amenable to specific targeting. Here, we report that the N-oxide AQ4N is reduced by a nitric oxide synthase. This reduction involves interaction with the heme iron atom in the active site and is thus subject to specific protein constraints.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anaerobiosis
  • Anthraquinones / chemistry
  • Anthraquinones / metabolism*
  • Binding Sites
  • Cytochrome P-450 CYP3A / metabolism
  • Heme / chemistry
  • Nitric Oxide Synthase / metabolism*
  • Nitric Oxide Synthase Type II / metabolism
  • Oxidation-Reduction
  • Prodrugs / metabolism*

Substances

  • Anthraquinones
  • Prodrugs
  • Heme
  • AQ4N
  • NOS2 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human